Abstract
Introduction
The subtype triple-negative breast cancer (TNBC) accounts for approximately 15%-25% of all breast cancer cases, and patients with TNBC have an increased risk of both local and distant recurrence and metastases compared to other breast cancers [1, 2] . Further, TNBC is characterized by a recurrence within 1-3 years and a high mortality rate [3] . Unfortunately, to date, treatment options for women with TNBC are limited. Therefore, it is important to identify key factors that facilitate tumor growth and/or metastases and may have the strong potential to serve as novel therapeutic targets to improve breast cancer treatment.
Mucins are a family of high molecular weight glycoproteins characterized by the presence of a heavily O-glycosylated tandem repeat region (TRR) that is rich in proline (P), threonine (T), and serine (S) residues, termed PTS sequences. The human mucin (MUC) family consists of members designated MUC1 to MUC21 that are typically expressed on the luminal surfaces of ductal epithelia. Under normal physiological conditions, mucins play a role in lubricating and protecting the epithelia of ducts, chemical sensing, and molecular configuration of the local cellular microenvironment [4] . Substantial evidence shows that mucins play a significant role in the progression of a variety of cancers in which their expression is deregulated; these cancers include pancreatic, ovarian, breast, colon, lung, and prostate [5] [6] [7] [8] [9] [10] .
Notably, among the several members of the mucin family, MUC1, MUC2, MUC3, MUC4, MUC5AC, and MUC6 are expressed in breast cancer. MUC1 and MUC3 are suggested as potential prognostic indicators, with MUC1 having the strongest relationship to patient outcomes [5] . Furthermore, MUC1 can interact and contribute to the activation of PI3K/AKT, ERK, and receptor tyrosine kinases (RTKs) to support the growth of breast cancer cells [11] . Importantly, MUC1 is aberrantly overexpressed in over 90% of early TNBC lesions, which can be attributed in part to genetic alterations as well as dysregulation of transcription. Further, overexpression of MUC1 is strongly associated with chemoresistance in breast cancer [6, 12, 13] . Much of the oncogenic potential role of MUC1 can be attributed to the participation of the small, cytoplasmic tail of MUC1 (MUC1.CT) in signal transduction and transcriptional events, facilitating growth and metastasis [8, [13] [14] [15] . Studies have demonstrated that MUC1.CT occupies multiple promoter elements in which MUC1.CT modulates the recruitment and activity of transcription factors, thus regulating transcription of corresponding genes [16] [17] [18] [19] .
Altered cellular metabolism is one of the hallmarks of cancer, and recently a functional role of MUC1 in tumorigenesis was highlighted by the observation that MUC1 plays a key role in tumor metabolism [18, 19] . Metabolic reprogramming facilitates chemoresistance and generates energy and biomass components to support rapidly proliferating tumor cells [20, 21] . Therefore, metabolic targets responsible for reprogramming cancer metabolism have the potential to serve as novel therapeutic targets. Recent studies indicate that MUC1 causes transcriptional alterations that result in metabolic reprogramming in cancer cells [18] . For example, our group demonstrated that MUC1 acts as a facilitator of glucose uptake and reprograms glycolytic metabolism in pancreatic cancer [18] . Our group also demonstrated that MUC1 physically occupies gene promoter regions and regulates expression of multiple genes involved in metabolic processes [18] . In the present study, the role of MUC1 expression was investigated with respect to triple-negative breast cancer (TNBC) metabolism. Utilizing in vitro modeling systems, results showed that altering MUC1 expression in turn altered metabolism in TNBC cell lines. Furthermore, results showed that MUC1 expression was associated with glutamine dependency in TNBC. Collectively the present study identifies MUC1 as a novel therapeutic target for breast cancer, particularly for the subtype TNBC. 
Material and methods

Cell culture
The TNBC cell lines MDA-MB-231 and MDA-MB-468 were purchased from American Type Culture Collection (ATCC, Manassas, VA). Cells were cultured in Dulbecco's Modified Eagle Medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 100 U/ml penicillin, and 100 μg/ml streptomycin in a humidified atmosphere at 37˚C with 5% CO 2 under atmospheric oxygen conditions (20%). Stable knockdown cells MDA-MB-468 were cultured in media supplemented with 2.5 μg/ml puromycin (Sigma-Aldrich, St. Louis, MO). For stable knockdown, cells were infected with shRNA lentiviral particles produced in HEK293T cells targeted to human MUC1 mRNA, as previously described [18] . MUC1-specific lentiviral shRNA plasmids were purchased from Sigma-Aldrich (St. Louis, MO).
Quantitative real-time polymerase chain reaction
Total RNA was lysed with Trizol reagent (Invitrogen Life Technologies, Carlsbad, CA) according to the manufacturer's protocol. Total RNA (3 μg) was reverse transcribed by utilizing Verso-cDNA synthesis kit (Thermo-Scientific, Waltham, MA) according to the manufacturer's protocol. Real-time polymerase chain reaction (RT-PCR) was performed in 384-well Optical Reaction Plates (Applied Biosystems, Foster City, CA) using a SYBRGreen PCR Master Mix (Roche, Dallas, TX). Reactions were performed on an ABI 7500 thermocycler (Applied Biosystems, Foster City, CA). All samples were amplified in duplicate, and quantification of the expression level of each gene was calculated using the delta-delta CT method and normalized to β-actin. Non-template controls were included for each primer pair. Data is presented by the fold change relative to the control.
Glucose uptake assay
Glucose uptake was determined as previously described [22, 23] . Briefly, 5 x 10 4 cells per well were seeded in a 24-well plate and allowed to adhere overnight. Cells were labeled with [ 
Glutamine uptake assay
Glutamine uptake was determined as previously described [22] . Briefly, 5 x 10 4 cells were seeded per well in a 24-well plate and allowed to adhere overnight. Cells were labeled with 3μCi 
Metabolite extraction and metabolomics
Metabolite extraction was performed as previously described [7, 24] . After confirming 80% confluence of the cells, culture media was replaced with fresh media for 2 hours prior to metabolite extraction. Media was aspirated, and the cells were washed twice with water to remove media remnants before lysing the cells. The polar metabolites were then extracted with a cryogenically cold, 80% methanol/water mixture. Metabolite extracts were analyzed using LC-MS/MS and a single reaction monitoring (SRM) method by utilizing AB SCIEX 5500 QTRAP1 (Framingham, MA), as described previously [24] . Data acquisition was carried out using Analyst™1.6 software (AB SCIEX, Framingham, MA), and peaks were integrated with Multiquant™ (AB SCIEX, Framingham, MA). Peak areas were normalized to the respective protein concentrations, and the resultant peak areas were subjected to relative quantification analyses with MetaboAnalyst 3.0 [25] .
Cell proliferation
For the cell proliferation assay, cells were seeded at a density of 5 x 10 3 cells/well in 96-well plates in triplicate. After 72 hours, cells were incubated with 20 μl of 3-(4,5-dimethyltiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT, Sigma-Aldrich, St. Louis, MO) (5 mg/ml) solution at 37˚C for 4 hours, followed by the addition of 100 μl of dimethyl sulfoxide (DMSO). The plates were read at 570 nm using a benchmark microplate reader (Biotek, Cytation 3, Winooski, VT).
Statistical analysis
Statistical comparisons between the two groups were performed utilizing the Student's t-test and comparison for the response to treatments was performed with ANOVA (one-way; Graph Pad Prism, Version 4.03). Tukey's post-hoc analysis was utilized for pair-wise comparisons.
Results
MUC1 expression induces metabolic alterations in TNBC cells
MUC1, a glycoprotein associated with chemoresistance, is known to be aberrantly overexpressed in over 90% of early TNBC lesions [6, 12, 13] . In the present study, to examine the role that MUC1 plays in metabolic alterations in TNBC, MUC1 was ectopically overexpressed in MDA To determine if altered MUC1 expression results in differential metabolism, we performed metabolomics using an LC-MS/MS platform. We observed metabolic differences between control (Neo or shScr) and experimental (MUC1 or shMUC1) cells. Principle component analysis (PCA) and hierarchical clustering analysis of the polar metabolites were utilized to determine metabolic differences between control and experimental cells (Fig 1) . As shown from the PCA data, polar metabolite profiles distinctly separated cells in a MUC1 expression-dependent manner, suggesting that altered MUC1 expression induced a significant change in the metabolite profile of the TNBC cells (Fig 1A and 1C) . Furthermore, heat maps of unsupervised hierarchical clustering indicated an overall metabolic distinction between control and experimental cells, evidenced by cells segregating into tight clusters (Fig 1B, 1D and 1E ).
Metabolite expression profiles in TNBC cells
To better understand the role of MUC1 in TNBC metabolism, individual metabolites were subjected to pathway impact analyses using metabolic pathways from the Kyoto Encyclopedia of Genes and Genomes (KEGG). These analyses identified highly significant enrichment of multiple pathways (Fig 2) . A number of the pathways are identified as amino acid metabolism pathways, indicating an alteration of amino acids biosynthesis and metabolism under conditions of MUC1 Fig 1. MUC1 regulates TNBC metabolism. Analysis was performed using MetaboAnalyst 3.0 on differentially expressed polar metabolites of the control (red) and experimental (green or blue) groups. Ovals represent 95% confidence interval for expression. Arginine and proline metabolism, alanine, aspartate and glutamate and D-glutamine and D-glutamate metabolism were amongst the most significantly altered pathways in MDA-MB-231 cells (Fig 2A) . Arginine and proline metabolism, glycine, serine and threonine metabolism, cysteine and methionine metabolism, alanine, aspartate and glutamate and D-glutamine and D-glutamate metabolism were among the redundant pathways identified in MDA-MB-468 cells (Fig 2B and 2C) . D-Glutamine and D-glutamate metabolism pathway was filtered out as potential target pathway for MDA-MB-231 and MDA-MB-468, with individual metabolites significantly altered within each pathway (Fig 3A) . Nitrogen metabolism was also filtered out which has an influence on the biosynthesis/metabolism of some amino acids (Fig 3B) . S1 and S2 Tables identify the corresponding metabolite to the KEGG compound.
MUC1 regulates glutamine metabolism in TNBC cells
Glucose and glutamine have been shown to play a role in promoting cancer growth, participating in energy formation, and redox homeostasis [26] . Therefore, glucose and glutamine uptake assays were utilized to determine the effect of altered MUC1 expression on [
H]-2DG and [
3 H]-glutamine uptake. As expected based on our previous data, MUC1 altered glucose uptake [18] in addition to glutamine uptake. Results showed that MUC1 overexpression significantly increased glucose and glutamine uptake in MDA-MB-231 cells, and MUC1 knockdown reduced glucose and glutamine uptake in MDA-MB-468 cells (Fig 4A and 4B) . These results indicate that MUC1 can facilitate the uptake of glucose and glutamine.
Evidence has shown that many cancer cells, including breast cancer, require glutamine for cell proliferation, TCA cycle intermediates, lipid synthesis, and neutralization of reactive oxygen species [27] . Therefore, the present study focused on D-glutamine and D-glutamate metabolism. To examine the role of MUC1 in glutamine metabolism, a panel of genes regulating glutamine metabolism was examined. Altered MUC1 expression resulted in a significant alteration in mRNA expression for SLC1A5, SLC38A2, GOT1, GLS2, GOT2, OGDH, and MYC (Fig 4C) . No change in mRNA levels of GLS1 was observed in either cell line. The effect of altered MUC1 expression on glutamine dependence in TNBC was then investigated (Fig 5) . As previously reported, MDA-MB-231 cells exhibited glutamine dependence [28] , but glutamine deprivation had no effect on MDA-MB-468 control cells (Fig 5A) . Cell viability assays revealed that MUC1 expression altered glutamine dependency compared to control cells. Further, results showed that glutamine dependency increased with MUC1 overexpression in MDA-MB-231 cells. Additionally, MUC1 knockdown decreased glutamine dependency in MDA-MB-468 cells. Glutamine dependency was further examined using the aminotransferase inhibitor aminooxyacetate (AOA). MUC1 expression altered cell survival in a dose-dependent manner, with increased cytotoxicity in the case of MUC1 overexpression in MDA-MB-231 cells and decreased cytotoxicity in the case of MUC1 knockdown in MDA-MB-468 cells (Fig  5B and 5C) . Collectively, these results indicate that altered MUC1 expression effects glutamine dependency in TNBC.
Discussion
In the present study, in vitro data support the theory that MUC1 serves as a metabolic regulator in TNBC. Glucose and glutamine serve as primary carbon sources in proliferating cells, and uptake of both of these nutrients is directed by growth factor signaling [29] . Further, metabolomics profiling identified metabolite alterations in which MUC1 expression modulates cancer cell metabolism to facilitate growth properties of TNBC cells (Fig 1) . Using pathway impact analyses, the top altered pathways were identified and include the following: the metabolism of arginine and proline, alanine, aspartate and glutamate, and D-glutamine and D-glutamate (Fig 2) . These pathways are all implicated in supporting cancer growth [30] [31] [32] .
Expression profiling of genes that regulate the metabolic processing of glutamine demonstrates that MUC1 can facilitate alterations of certain key genes in TNBC (Fig 4) . Altered glutamine metabolism is reported in several cancers [27, 33, 34] . Glutamine can be a nitrogen donor for multiple essential biosynthetic reactions in the cell [32, 35] . MUC1 facilitated alterations in the expression of genes SLC1A5 and SLC38A2 thereby modifying glutamine transportation. Once taken up by the cell, much of the glutamine is converted to glutamate by mitochondrial glutaminase, an enzyme whose levels are often upregulated in cancer [36, 37] . Both glutamine and glutamate contribute to anabolic metabolism; glutamine supplies nitrogen for nucleotide and hexosamine synthesis, while glutamate is the nitrogen donor for the synthesis of many nonessential amino acids. In our study, MUC1 overexpression facilitated the increase in the gene GLS2, but no alteration was observed in GLS1 (Fig 4) . Glutamate can then be converted to α-ketoglutarate, which enters the TCA cycle to generate ATP through production of nicotinamide adenine dinucleotide (NADH) and flavin adenine dinucleotide (FADH 2 ). Glutamate is converted to α-ketoglutarate by glutamate-oxaloacetate transaminase (GOT), which transfers nitrogen from glutamate to oxaloacetate to produce aspartate and α-ketoglutarate, is encoded in humans by (1) GOT1 (cytoplasmic isoform) or (2) GOT2 (mitochondrial isoform). MUC1 overexpression significantly increased the expression of GOT1 and GOT2, while MUC1 knockdown significantly decreased the expression of GOT1. Additionally, we observed MUC1-mediated changes in oxoglutarate dehydrogenase (OGDH) . A recent study demonstrated that inhibiting OGDH impairs cell viability [38] . Hence, MUC1-mediated upregulation of OGDH might be responsible for the increased TCA cycle flux to promote growth in TNBC cells. Furthermore, the observed alterations in glucose and glutamine uptake (Fig 4) suggest that MUC1 facilitates the utilization of both glucose and glutamine as carbon sources to maximize ATP production.
Under reduced glutamine conditions, cell survival decreased significantly in MDA-MB-231 cells with MUC1 overexpression, but cell survival increased in MDA-MB-468 cells with MUC1 knockdown (Fig 5) . The nitrogen obtained from glutamine is essential in fueling amino acid pools in the cell through the action of aminotransferases. Studies have shown that at least 50% of non-essential amino acids used in protein synthesis by cancer cells in vitro can be directly derived from glutamine [39] . Considering that amino acids are the building blocks of proteins and essential for cell growth, studies herein with the aminotransferase inhibitor AOA showed that aminotransferases are required for glutamine to sustain cell survival. As shown in Fig 5, altered MUC1 expression affected AOA-mediated cytotoxicity. MUC1 overexpression increased cell sensitivity to AOA, while MUC1 knockdown decreased cell sensitivity to AOA. These results suggest MUC1 expression regulates glutamine dependency, and treatment with AOA or glutamine depletion sensitizes cells mainly by depleting pools of amino acids (Fig 6) .
In conclusion, our study evidences a vital role for MUC1 in TNBC and a potential mechanism by which MUC1 contributes to the metabolic process involved breast cancer. Our data identify MUC1 as essential for cell proliferation and survival, which is mediated, at least in part, by glutamine metabolism. The data also support a potential therapeutic role for targeting aminotransferases, particularly in MUC1-overexpressing TNBC. Finally, our data suggest that MUC1 represents a potential novel therapeutic target to reduce tumor growth in breast cancer. 
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